Innovative Medical Imaging.
Oncovision is a leading provider of innovative medical imaging devices used by surgeons, radiologists, oncologists and nuclear physicians for the diagnosis and treatment of cancer.
Oncovision has grown into a dynamic brand in a technologically competitive, high-growth industry. Oncovision has offices in Boston, USA and Valencia, Spain and sells its products in over 30 markets through a combination of direct sales and distributors.
Through a strong internal pipeline, Oncovision boasts a clinical and preclinical product line. Clinical product line includes market-leading Sentinella, a unique intra-operative Gamma Camera and the revolutionary Mammi PET, a breast cancer diagnostic device capable of visualising lesions of less than 2mm and quantifying tumor activity. Oncovision completes its portfolio with Wprobe, the gold standard in radioguided surgery.
Oncovision has distinguished itself through the ability to successfully develop and bring to the market innovative products to generate significant benefits on patients, and is committed to continue that trend. Also, the company plans to bring forth technical and clinical solutions for an accurate diagnosis and treatment of cancer, providing the highest-quality, best-performing products.
Our values are the beliefs we all share, that drive our company personality, culture, and priorities. They provide a framework for making decisions and the how Oncovision employees are expected to conduct themselves in a professional and responsible manner.
The Oncovision Code of Conduct contains important information and resources to guide you in conducting business legally, ethically, and responsibly in accordance with our shared values.
Build a best in class international organization to achieve leadership in focused markets, leveraging innovative imaging technologies that result in improved patient quality of life and healthcare professionals experience.
We change the practice of medicine with solutions that speed detection, diagnosis and treatment while improving patient lives care. Transforming the cure of cancer, through the creation of new standard diagnostic tests and treatment in multimodal molecular vision technologies for surgery, diagnosis, intervention and advanced research with clinical and economic advantages.
Accountability: Do the right thing and be proud of it.
Innovation: Deliver the wow factor in technology.
Focus: Concentrate on what is important by listening the market needs.
Professionalism: Build open honest relationship with everyone.
Improvement: Aim to be the best every day. Think Smart, Act Smart.
The Oncovision Code of Conduct is the ethical foundation of our business and supports our values.
CHIEF EXECUTIVE OFFICER:
Ignasi Vivas joined Oncovision in October 2015 as Chief Executive Officer with more than 15 years of healthcare experience. Prior to joining Oncovision he held various VP positions at Acelity, Lifecell and Angiodynamics. Ignasi started his medical device career at American Medical Systems in Minneapolis and then grew to different positions of responsibility across Europe. Prior entering the medical device world, Mr. Vivas worked as a registered pharmacist and a registered optometrist for a number of years. Mr. Vivas has a proven track record in developing and implementing growth strategies in the medical device and healthcare industries in the U.S., Europe, the Middle East, Asia and Latin America. He has a bachelor’s degree in Pharmacy and Optometry from the University of Barcelona and a Masters of Business Administration from the University of North Carolina, Kenan-Flagler Business School.
COMMERCIAL DIRECTOR EMEA & APAC:
Javier Calonge joined Oncovision in February, 2016 as Commercial Director EMEA and APAC. He has more than 15 years of experience in commercial operations in diverse business environments, and a proven track record of growing revenue and EBITDA, improving customer satisfaction, and driving operational excellence. Prior to joining Oncovision, Mr. Calonge served as General Manager for Iberica at Acelity. Before that, he held positions of increasing responsibility at Novartis, Lacer, Ethicon and Lifecell. He received a B.S. in Business Administration and a Social Degree in BA by the State University of New York.
COMMERCIAL DIRECTOR AMERICAS:
Raizza Luzzi joined Oncovision in February, 2016 as Commercial Director America. She has more than 15 years of experience in commercial operations in the US and Latin American Markets through direct and distributor operations. Prior to joining Oncovision, Mrs. Luzzi served as a consultant for several US and EU Medical Device companies in Latin America, gaining great understanding of the capital equipment business and the importance of working together with distributors. Raizza holds a bachelor degree in political science with a minor in International business from the University of Southern Florida.
Elena joined Oncovision in March 2016 as International Marketing & Training Director. She has 10 years of experience in Marketing & Sales. Prior joining Oncovision she had a successful career in Marketing at Acelity where she held different positions in Marketing and Management. Prior to Acelity she worked at Hologic in various roles in the gyn division and previously worked at Astellas in their Training department. Elena has a great understanding of the medical device industry having work as a practitioner as well as a sales manager and marketer. She holds an Emergency nursing degree and a Master in Healthcare Business Administration from the Universidad Europea.
CHIEF FINANCIAL OFFICER:
Maite Montemayor holds a bachelor degree in actuarial science and finance and a Bachelor degree in business administration from the University of Valencia. Mrs Montemayor joined Oncovision in August, 2008 as Finance Director. She has more than 12 years of experience in financial services for different companies. Before joining Oncovision, Mrs. Montemayor was Senior Audit Manager at Ernst and Young. Prior to that, Maite served in different roles at KPMG. She is responsable of the following functions: Accounting analysis, analytical costs, external and internal audit, negotiation with banks, economic and financial management of capital increases and structured debt, reporting to the board.
CHIEF OPERATIONS OFFICER:
Carlos Aguilar is an experienced Chief Operating Officer (COO), responsible for R&D and Operations. He is a seasoned director with almost 30 years of engineering and managerial work experience. He has a degree in industrial engineering specializing in electronics in Valencia, and has held different responsibilities in companies as IBM, MSL or Celestica. His large experience involves several roles as New Projects Director, R&D, Operations, Strategic Projects and Engineering Services. His wealth of experience is highly valuable to Oncovision.
Maria Climent has a wide experience as Quality Manager in medical equipment and pharmaceutical companies. She has worked for more than 15 years implementing quality standards in different countries and managing continuous improvement within her companies. Her professional experience has been developed in different areas at an International level, including; Naturex, Valencian Institute of Infertility (IVI), and Natra. She assures quality products and processes by establishing and enforcing quality standards. Her dedication to continuous improvement has enabled her to improve customer satisfaction, one of the basic pillars of a company. She holds a Ph.D. in Pharmacy from the University of Valencia and holds a Master’s Degree in Quality and Environment from the Universidad Complutense de Madrid.
Enrique Diaz-Laugart joined Oncovision in July 2015, as Clinical Specialist and got promoted to Clinical Director in January 2017. He has a medical degree in Nuclear Medicine and Molecular Imaging, with specific training in biomedical imaging since 2013, and Medicine & Surgery Degree since 1998. MD. Diaz has a good understanding of radiation physics, radiochemistry and has been involved and manage many Clinical Trials including lesion localization with low dose radioactive seeds (LDRS), radio-guided surgery and the first treatment with 177Lu-DOTA-Tyr-Octreotate. His long experience on the field will guaranteed the success of the clinical development.
The following companies and organizations have collaborated in the development of Oncovision products: